Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
复制标题
DOI：
10.1186/s12885-020-07544-3
复制
发表时间：
2020-10-29
期刊：
影响因子：
3.8
通讯作者：
Jang SH
中科院分区：
文献类型：
--
作者：
Park JY;Lee YJ;Kim T;Lee CY;Kim HI;Kim JH;Park S;Hwang YI;Jung KS;Jang SH
由于2019冠状病毒病进展迅速且死亡率高，预计其将对肺癌患者产生重大影响。缺乏流行期间肺癌诊断和治疗的研究。我们分析了COVID-19对韩国肺癌诊断的影响，韩国肺癌发病率持续上升。将疫情期间三所大学附属医院的肺癌新发病例数及其临床特征与过去3年同期确诊的肺癌病例进行比较。对研究医院采取的预防院内传播措施的有效性进行了审查。从2017年2月至2020年6月，共有612名患者被诊断患有肺癌。疫情期间，到研究医院肺科就诊的患者人数较上年下降16%。为应对疫情，相关医院为有急性呼吸道感染症状的患者设立了物理隔离的分诊区。实施了广泛的筛查和预防措施，从而最大限度地减少了肺癌诊断的延误。没有患者因医院暴露而感染COVID-19。III-IV期非小细胞肺癌（NSCLC）患者比例显著增加（2020年：74.7%对比2017年：57.9%，2018年：66.7%，2019年：62.7%，p = 0.011）。在这一期间和前一年诊断出的肺癌人数保持不变。在COVID-19大流行期间，晚期非小细胞肺癌患者的比例有所增加。在线版本包含补充材料，可通过10.1186/s12885-020-07544-3获得。
The COVID-19 pandemic is predicted to significantly affect patients with lung cancer, owing to its rapid progression and high mortality. Studies on lung cancer diagnosis and treatment during an epidemic are lacking. We analyzed the impact of COVID-19 on lung cancer diagnosis in Korea, where lung cancer incidence continues to rise. The number of newly diagnosed lung cancer cases in three university-affiliated hospitals during the pandemic and their clinical features were compared with lung cancer cases diagnosed during the same period in the past 3 years. The effectiveness of measures taken by the study hospitals to prevent nosocomial transmission was reviewed. A total of 612 patients were diagnosed with lung cancer from February through June, 2017–2020. During the pandemic, the number of patients who sought consultation at the division of pulmonology of study hospitals dropped by 16% from the previous year. Responding to the pandemic, the involved hospitals created physically isolated triage areas for patients with acute respiratory infection symptoms. Wide-range screening and preventive measures were implemented, thus minimizing the delay in lung cancer diagnosis. No patient acquired COVID-19 due to hospital exposure. The proportion of patients with stage III–IV non-small-cell lung cancer (NSCLC) significantly increased (2020: 74.7% vs. 2017: 57.9%, 2018: 66.7%, 2019: 62.7%, p = 0.011). The number of lung cancers diagnosed during this period and the previous year remained the same. The proportion of patients with advanced NSCLC increased during the COVID-19 pandemic. The online version contains supplementary material available at 10.1186/s12885-020-07544-3.
登录
查看更多内容
影响因子：
24.3
作者：
Buccheri, G;Ferrigno, D
通讯作者：
Ferrigno, D
影响因子：
5.8
作者：
Al-Shamsi, Humaid O.;Alhazzani, Waleed;Xie, Conghua
通讯作者：
Xie, Conghua
影响因子：
51.1
作者：
Sud, Amit;Torr, Bethany;Turnbull, Clare
通讯作者：
Turnbull, Clare
DOI：
10.1016/j.annonc.2020.05.009
发表时间：
2020-08-01
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Sud, A;Jones, M E;Turnbull, C
通讯作者：
Turnbull, C
影响因子：
4.6
作者：
Yuan P;Cao JL;Rustam A;Zhang C;Yuan XS;Bao FC;Lv W;Hu J
通讯作者：
Hu J